EP1036794A4 - 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate - Google Patents

2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate

Info

Publication number
EP1036794A4
EP1036794A4 EP98955937A EP98955937A EP1036794A4 EP 1036794 A4 EP1036794 A4 EP 1036794A4 EP 98955937 A EP98955937 A EP 98955937A EP 98955937 A EP98955937 A EP 98955937A EP 1036794 A4 EP1036794 A4 EP 1036794A4
Authority
EP
European Patent Office
Prior art keywords
same
aryl
intermediates
producing
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98955937A
Other languages
English (en)
French (fr)
Other versions
EP1036794A1 (de
EP1036794B1 (de
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Priority to SI9830507T priority Critical patent/SI1036794T1/xx
Publication of EP1036794A1 publication Critical patent/EP1036794A1/de
Publication of EP1036794A4 publication Critical patent/EP1036794A4/de
Application granted granted Critical
Publication of EP1036794B1 publication Critical patent/EP1036794B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP98955937A 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate Expired - Lifetime EP1036794B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9830507T SI1036794T1 (en) 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03
JP35000097 1997-12-03
PCT/JP1998/005320 WO1999028320A1 (fr) 1997-12-03 1998-11-26 Derives de 2-aryl-8-oxodihydropurine, procede de production de ces derives, compositions medicales contenant ces derives, et intermediaires de ces derives

Publications (3)

Publication Number Publication Date
EP1036794A1 EP1036794A1 (de) 2000-09-20
EP1036794A4 true EP1036794A4 (de) 2001-12-12
EP1036794B1 EP1036794B1 (de) 2003-08-27

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98955937A Expired - Lifetime EP1036794B1 (de) 1997-12-03 1998-11-26 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate

Country Status (27)

Country Link
US (1) US6372740B1 (de)
EP (1) EP1036794B1 (de)
JP (1) JP3815966B2 (de)
KR (1) KR100494347B1 (de)
CN (1) CN1146566C (de)
AR (1) AR017796A1 (de)
AT (1) ATE248169T1 (de)
AU (1) AU744014B2 (de)
BR (1) BR9815140A (de)
CA (1) CA2312885C (de)
DE (1) DE69817611T2 (de)
DK (1) DK1036794T3 (de)
ES (1) ES2205574T3 (de)
HK (1) HK1028769A1 (de)
HU (1) HUP0004422A3 (de)
ID (1) ID24929A (de)
IL (1) IL135920A0 (de)
NO (1) NO20002835L (de)
NZ (1) NZ504457A (de)
PL (1) PL191489B1 (de)
PT (1) PT1036794E (de)
RU (1) RU2223272C2 (de)
SK (1) SK285703B6 (de)
TR (1) TR200001600T2 (de)
TW (1) TW502034B (de)
WO (1) WO1999028320A1 (de)
ZA (1) ZA9810490B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
NZ517962A (en) * 1999-09-27 2003-11-28 Ono Pharmaceutical Co Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient
EP1306378A4 (de) * 2000-07-31 2005-02-09 Dainippon Pharmaceutical Co Heilmittel zur behandlung von dementia die 2-aryl-oxodihydropurin-derivate als aktiven wirkstoff enthalten
AU2004263515A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
AU2005214258A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
EP1734820A4 (de) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrazine, imidazopyridine und imidazopyrimidine als crf1-rezeptorliganden
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
KR20080013886A (ko) * 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101454325A (zh) * 2006-03-09 2009-06-10 法马科皮亚公司 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂
WO2008043019A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
WO2008043031A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
KR101820541B1 (ko) * 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-옥소디히드로퓨린 유도체
ES2613664T3 (es) 2009-10-26 2017-05-25 Signal Pharmaceuticals, Llc Procedimientos de síntesis y purificación de compuestos de heteroarilo
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
US20140301947A1 (en) 2011-06-06 2014-10-09 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
BR112014009755B1 (pt) 2011-10-19 2022-09-13 Signal Pharmaceuticals, Llc Tratamento de câncer com inibidores de quinase tor
CA3125862A1 (en) 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
BR112014020786A2 (pt) 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
PE20160041A1 (es) 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
TWI631950B (zh) 2013-04-17 2018-08-11 標誌製藥公司 藉二氫吡𠯤并吡𠯤治療癌症
EP2986321A1 (de) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Kombinationstherapie mit einem torkinaseinhibitor und einem cytidinanalogon zur behandlung von krebs
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
MX2021001186A (es) 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP3752505B1 (de) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Neuartige sulfonverbindungen und derivate zur behandlung und prophylaxe einer virusinfektion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
AU751710B2 (en) * 1997-04-22 2002-08-22 Neurocrine Biosciences Inc. CRF antagonistic thiophenopyridines
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
ES2205574T3 (es) 2004-05-01
EP1036794A1 (de) 2000-09-20
JP3815966B2 (ja) 2006-08-30
KR100494347B1 (ko) 2005-06-13
NO20002835L (no) 2000-07-24
PL340925A1 (en) 2001-03-12
US6372740B1 (en) 2002-04-16
WO1999028320A1 (fr) 1999-06-10
IL135920A0 (en) 2001-05-20
DE69817611T2 (de) 2004-02-26
AR017796A1 (es) 2001-10-24
ZA9810490B (en) 1999-05-20
NO20002835D0 (no) 2000-06-02
ATE248169T1 (de) 2003-09-15
PL191489B1 (pl) 2006-05-31
PT1036794E (pt) 2003-11-28
HUP0004422A3 (en) 2001-10-29
TW502034B (en) 2002-09-11
EP1036794B1 (de) 2003-08-27
CA2312885C (en) 2008-01-29
HUP0004422A2 (hu) 2001-04-28
NZ504457A (en) 2001-12-21
SK285703B6 (sk) 2007-06-07
CA2312885A1 (en) 1999-06-10
AU744014B2 (en) 2002-02-14
AU1260499A (en) 1999-06-16
DE69817611D1 (de) 2003-10-02
ID24929A (id) 2000-08-31
SK7972000A3 (en) 2001-03-12
DK1036794T3 (da) 2003-12-22
TR200001600T2 (tr) 2000-11-21
HK1028769A1 (en) 2001-03-02
KR20010032686A (ko) 2001-04-25
BR9815140A (pt) 2000-10-10
CN1146566C (zh) 2004-04-21
RU2223272C2 (ru) 2004-02-10
CN1284076A (zh) 2001-02-14

Similar Documents

Publication Publication Date Title
EP1036794A4 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
WO2001072728A3 (en) Novel piperazine derivatives
WO1995029917A3 (en) Intermediates in pharmaceutical camptothecin preparation
CA2333938A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
AU2420897A (en) Meta-substituted phenylene sulphonamide derivatives
WO1998035951A3 (en) New aminopiperazine derivatives
WO1999064409A3 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU8000594A (en) Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
CA2168097A1 (en) Substituted 2-aminotetralins
ATE218345T1 (de) Arzneimittel gegen spinocerebellare degeneration
WO1999009025A3 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
EP0716083A4 (de) Benzazepin-derivate, diese enthaltende pharmazeutische präparate sowie zwischen-produkte zur herstellung
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
CA2219656A1 (en) Antibacterial cephalosporins
CA2226886A1 (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
WO2000046210A3 (en) New process for preparing pesticidal intermediates
PL315052A1 (en) Condensed dihydropyridines, method of obtaining them, their application in producing pharmaceutic preparations and pharmaceutic preparations containing such compounds
CA2300289A1 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
NO20004919D0 (no) FremgangsmÕte for fremstilling av 5-hydroksybenzo[b]tiofen-3- karboksylsyrederivater
EP0754683A4 (de) Etherverbindungen, ihre verwendung und zwischenprodukte zu ihrer herstellung
NZ332545A (de)
EP1026162A4 (de) Antirheumatika
WO2000018722A3 (es) Nuevos derivados de la 6-(4-fenilbutoxi)hexilamina y procedimiento para la obtencion de salmeterol
WO2001010861A3 (de) Substituierte heterocyclyl-2h-chromene
WO2002060878A1 (en) Benzimidazolidinone derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000623;LT PAYMENT 20000623;LV PAYMENT 20000623;RO PAYMENT 20000623;SI PAYMENT 20000623

A4 Supplementary search report drawn up and despatched

Effective date: 20011026

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020422

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69817611

Country of ref document: DE

Date of ref document: 20031002

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030404134

Country of ref document: GR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2205574

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040528

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD.

Free format text: DAINIPPON PHARMACEUTICAL CO., LTD.#6-8, DOSHO-MACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-8524 (JP) -TRANSFER TO- DAINIPPON SUMITOMO PHARMA CO., LTD.#6-8 DOSHO-MACHI 2-CHOME CHUO-KU, OSAKA-SHI#OSAKA-FU (JP)

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD.; JP

Effective date: 20060321

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: DAINIPPON SUMITOMO PHARMA CO. LTD.

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

REG Reference to a national code

Ref country code: PT

Ref legal event code: PD4A

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD, JP

Effective date: 20060306

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20071003

Year of fee payment: 10

Ref country code: DK

Payment date: 20071115

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20071004

Year of fee payment: 10

Ref country code: GR

Payment date: 20070928

Year of fee payment: 10

Ref country code: CY

Payment date: 20071002

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20081130

Year of fee payment: 11

Ref country code: LU

Payment date: 20081127

Year of fee payment: 11

Ref country code: IE

Payment date: 20081002

Year of fee payment: 11

Ref country code: DE

Payment date: 20081120

Year of fee payment: 11

Ref country code: CH

Payment date: 20081106

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20081015

Year of fee payment: 11

Ref country code: ES

Payment date: 20081128

Year of fee payment: 11

Ref country code: AT

Payment date: 20081124

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20081013

Year of fee payment: 11

Ref country code: IT

Payment date: 20081112

Year of fee payment: 11

Ref country code: SE

Payment date: 20081107

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081124

Year of fee payment: 11

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20090526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081120

Year of fee payment: 11

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081130

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081126

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20090813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090603

BERE Be: lapsed

Owner name: *DAINIPPON SUMITOMO PHARMA CO. LTD

Effective date: 20091130

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20100601

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20091126

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100601

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091127

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20111116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091127